Larazotide: The Tight Junction Peptide That Reached Phase 3

Larazotide acetate is an eight-amino-acid peptide that regulates tight junctions — the seals between intestinal epithelial cells. When those seals loosen, molecules cross the gut lining that normally would not. Larazotide is intended to tighten them.

It is unusual in this category because it progressed through a full clinical development programme, reaching phase 3 for coeliac disease. That history is more informative than any mechanism description.

What tight junctions do

The intestinal lining is a single cell layer with protein complexes sealing the gaps between cells. Those complexes open and close under regulation — they are meant to be dynamic, not permanently shut.

Zonulin is a protein that increases permeability by acting on these junctions. Larazotide was designed as a zonulin antagonist: block that signal and the junctions stay tighter.

What happened in development

Larazotide was developed for coeliac disease as an adjunct to a gluten-free diet — addressing residual symptoms in people already avoiding gluten. It advanced through phase 2 with encouraging signals and into phase 3.

The phase 3 programme did not deliver the result required to carry it to approval. Development for that indication did not produce an approved product.

Why "leaky gut" language attaches to it

Intestinal permeability is a real, measurable phenomenon studied in coeliac disease, inflammatory bowel disease, and other conditions. "Leaky gut" as a popular term covers a much broader and vaguer set of claims.

Larazotide is genuinely a permeability-modulating compound, which is why it gets adopted into that conversation. The specific, evidence-based version of the claim is narrow; the popular version is not.

Oral by design

Larazotide acts locally in the gut lumen and was developed as an oral formulation. It is not intended to be absorbed systemically — reaching the bloodstream would defeat the purpose.

That makes injecting it mechanistically incoherent: the target is the luminal side of the intestinal lining. It shares that local-action logic with KPV in gut-focused research, where route is equally central.

Frequently asked questions

Is larazotide approved?

No. It reached phase 3 for coeliac disease without securing approval.

Does it treat leaky gut?

It modulates intestinal permeability, which is a measurable phenomenon. Whether that addresses the broad set of claims made under the popular term is a different and much less well-defined question.

Should it be injected?

It was designed to act locally in the gut lumen and to avoid systemic absorption. An injectable presentation works against the mechanism it was built around.